PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, today announced the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (“RLS”). The assets were previously dedicated to the study of suramin’s potential efficacy in treating acute kidney injury resulting from chronic kidney disease. According to the announcement, … Continue reading InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Acquires Research Assets to Accelerate PAX-101 NDA Submission